Infliximab: adverse events as reason for treatment discontinuation

被引：0
作者：
Moustou, A. -E. [1 ]
Papoutsaki, M. [1 ]
Vergou, T. [1 ]
Masouri, S. [1 ]
Sachlas, A. [2 ]
Antoniou, C. [1 ]
机构：
[1] A Sygros Hosp, Dept Dermatol 1, Athens, Greece
[2] Univ Peloponnese, Dept Nursing, Sparta, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
adverse events; infliximab; treatment discontinuation;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P184
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [31] Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample
    Yeaw, Jason
    Watson, Crystal
    Fox, Kathleen M.
    Schabert, Vernon F.
    Goodman, Seth
    Gandra, Shravanthi R.
    ADVANCES IN THERAPY, 2014, 31 (04) : 410 - 425
  • [32] A Systematic Review and Meta-analysis of the Efficacy and Adverse Events of Infliximab in Comparison to Corticosteroids and Placebo in Active Ulcerative Colitis
    Nikfar, Shekoufeh
    Ehteshami-Afshar, Solmaz
    Abdollahi, Mohammad
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2011, 7 (03) : 325 - 332
  • [33] Adverse events in patients with leprosy on treatment with thalidomide
    de Miranda Drummond, Paula Lana
    Marques dos Santos, Roberta Marcia
    Carvalho, Gabriela Oliveira
    Menezes de Padua, Cristiane Aparecida
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2019, 52
  • [34] Adverse events of sorafenib in hepatocellular carcinoma treatment
    Pang, Yongsheng
    Eresen, Aydin
    Zhang, Zigeng
    Hou, Qiaoming
    Wang, Yining
    Yaghmai, Vahid
    Zhang, Zhuoli
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2770 - 2782
  • [35] Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab
    Ksienski, Doran
    Truong, Pauline T.
    Croteau, Nicole S.
    Chan, Angela
    Sonke, Eric
    Patterson, Tiffany
    Clarkson, Melissa
    Hackett, Samuel
    Lesperance, Mary
    JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (02) : 220 - 227
  • [36] Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
    Johansson, K.
    Neovius, K.
    DeSantis, S. M.
    Rossner, S.
    Neovius, M.
    OBESITY REVIEWS, 2009, 10 (05) : 564 - 575
  • [37] Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
    Theodoraki, Eirini
    Orfanoudaki, Eleni
    Foteinogiannopoulou, Kalliopi
    Legaki, Evangelia
    Gazouli, Maria
    Koutroubakis, Ioannis E.
    INTESTINAL RESEARCH, 2021, 19 (04) : 461 - 467
  • [38] Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission
    Munoz Villafranca, Carmen
    Bravo Rodriguez, Maria Teresa
    Ortiz de Zarate, Jone
    Arreba Gonzalez, Paz
    Garcia Kamiruaga, Inigo
    Heras Martin, Juan Ignacio
    Cabezudo Gil, Pilar
    Orive Cura, Victor
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (07): : 442 - 448
  • [39] Treatment-emergent adverse events and antiseizure medication actual drug load
    Pretat, Tiffany
    Aicua-Rapun, Irene
    Andre, Pascal
    Lebon, Sebastien
    Rossetti, Andrea O.
    Decosterd, Laurent A.
    Buclin, Thierry
    Novy, Jan
    EPILEPSY & BEHAVIOR, 2022, 137
  • [40] Adverse events and preventable adverse events in children
    Woods, D
    Thomas, E
    Holl, J
    Altman, S
    Brennan, T
    PEDIATRICS, 2005, 115 (01) : 155 - 160
12345